Sign in
TerminatedPhase 4

Tianeptine for Treatment Resistant Depression

Key facts

Who runs it
Jonathan A. Javitch, MD, PhD
Where
New York and Stanford, United StatesSee the 3 sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
38 people enrolled
Started
14 Oct 2020
Ended
27 Aug 2024
Type of study
Interventional
Treatments tested
  • Tianeptine Sodium
Record updated
23 January 2026
Why it stopped
Inadequate recruitment

Who can take part

Age
21 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age 21 - 60 years, male or female
  • Current diagnosis of Major Depressive Disorder (MDD) without psychotic features
  • 24-item Hamilton Rating Scale for Depression (HRSD) ≥ 16
  • At least two previous antidepressant treatment failures (adequate trials within current episode) with a SSRI, SNRI, bupropion, tricyclic antidepressant, mirtazapine, nefazodone, or monoamine oxidase inhibitor, or transcranial magnetic stimulation (TMS), or IV ketamine or nasal ketamine
  • Capable of providing informed consent and complying with study procedures
  • Currently using or willing to use contraception, if woman of childbearing potential (such as condoms, IUD, or oral contraceptive), for duration of the study

Who cannot take part

  • Previous or current treatment with Tianeptine
  • Current treatment or currently taking an opioid
  • Failed depression treatment with electroconvulsive therapy
  • Currently being treated with an antidepressant medication, an antipsychotic or mood stabilizer; If a participant is taking a protocol dis-allowed medication at the time of screening and despite medication treatment still meets the inclusion criteria of an HRSD>16, the participant may discontinue the medication under the supervision of their treating physician or the study clinician
  • Any history of opioid-use disorder
  • Any history of moderate- non-opioid (except for Nicotine) substance-use disorder
  • Any severity of alcohol use disorder (including mild)
  • Past or current psychosis, psychotic disorder (including psychotic MDD), mania, or bipolar disorder
  • Acute, severe, or unstable medical illness
  • Hamilton Rating Scale for Depression (HRSD) suicide item > 2 or Clinical Global Impressions (CGI)-Severity score of 7 at baseline
  • Weight > 300 lbs, or girth size incompatible with scanner bore
  • Any physical or intellectual disability adversely affecting ability to complete assessments. MMSE <26
  • for MSSM site - Having contraindication to MRI scanning (such as metal in body) or inability to tolerate the scanning procedures (e.g., severe obesity, claustrophobia)
  • Current pregnancy or currently breast feeding
  • Abnormal baseline liver function tests
  • Positive urine toxicity at screening (except for cannabinoid)

Where in United States

  • Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount SinaiNew York, United States
  • New York State Psychiatric InstituteNew York, United States
  • Stanford Depression Research Clinic at Stanford University School of MedicineStanford, United States

About the trial

What the trial wants to find out

The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of Medicine (SUSM). In addition, MRI studies for the MSSM patients will be carried out at the New York State Psychaitric Institute (NYSPI). The following procedures will be approved by the local Institutional Review Boards (IRBs) at each site, where the site PIs (Alla Landa, PhD, NYSPI, James Murrough, MD at MSSM, and Alan Schatzberg, MD at SUSM) will be responsible for overseeing conduct of the study at their respective site. Dr. Jonathan Javitch is the scientific leader of this program and holds the IND for tianeptine use in this study.

Read full original descriptionShow less

Investigators will recruit 75 participants with current unipolar MDD, non-delusional, between 21-60, who have failed at least 2 two adequate treatment trials with a standard antidepressant. Patients will receive an 8-week treatment trial of tianeptine. MSSM patients will also undergo structural and task-based magnetic resonance imaging (MRI) that will be performed under Dr. Landa's direction at NYSPI in order to maintain the internal validity of the data set. MSSM subjects will be transported to NYSPI to complete neuroimaging procedures as described below. Participants will be screened for MRI clearance during their screening visit and again at NYSPI on the day of the scan. Subjects will be asked MRI screening questions to ensure that are scanning eligible. Participants will also have additional tubes of blood drawn for human whole-genomic testing. This microarray will be used to identify regions of the human genome that contribute to disease susceptibility and phenotypes. The Illumina human whole-genome array will be used to provide a comprehensive view of the genome, detects single nucleotide polymorphisms and other variations across the genome.

The group in the trial

  • Open TreatmentTreatment being tested

    All subjects will be treated for 8 weeks of treatment with Tianeptine (Tianeurax 12.5 mg) 3 times a day (9am, 1pm, 5pm).

    Treatment: Tianeptine Sodium

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 January 2026